Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Arix Bioscience plc. (8/6/18). "Press Release: Arix Bioscience Announces First VIPE Investment". London.

Region Region Australia
Organisations Organisation Arix Bioscience plc (LSE: ARIX)
  Today Arix Bioscience (Group)
  Group Arix Bioscience (Group)
  Organisation 2 Pharmaxis Ltd. (ASX: PXS)
Products Product LOXL-2 inhibitor (Lysyl Oxidase-Like type 2 inhibitor)
  Product 2 venture capital
Index terms Index term Pharmaxis–SEVERAL: investment, 201808– primary placing A$24m in two tranches led by Arix Bioscience
  Index term 2 Pharmaxis–Arix Bioscience: investment, 201808– primary placing totalling A$24m incl A$14.2m in two tranches from lead investor Arix Bioscience
Persons Person Rayner, Edward (Arix Bioscience 201808)
  Person 2 Phillips, Gary (Pharmaxis 201505 CEO)

> Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis

> Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company advances numerous candidates from its Amine Oxidase drug discovery platform

> First Venture Investment in Public Equity (VIPE) led by Arix, taking core portfolio to 14 companies

Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an 11 per cent interest in Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.

The A$24 million (£13.4 million) primary placing was led by Arix Bioscience and included participation from existing investors BVF Partners L.P., and supported by other existing shareholders. Arix Bioscience has invested A$14.2 million (£8.0 million) in a two tranche placement, and following shareholder approval of the second tranche, Arix will hold approximately 11 per cent of the total outstanding shares of Pharmaxis. The Pharmaxis Board has approved the nomination of Arix’s Edward Rayner to join the Board at the EGM in September 2018.

Pharmaxis’ lead development programme is an anti-fibrotic Lysyl Oxidase-Like type 2 (LOXL2) inhibitor. This is an exciting enzymatic target that acts at a crucial stage of pathogenic fibrosis. The net proceeds of the placing will be used to further develop the programme for the treatment of a range of fibrotic diseases, including Non-alcoholic Steatohepatitis (NASH), Idiopathic Pulmonary Fibrosis (IPF), heart and kidney fibrosis. The first stage of phase 1 studies has demonstrated a best in class profile for LOXL-2 inhibitors with two compounds achieving significant and long-lasting inhibition of LOXL-2 enzyme after a single oral dose. The final stages of the phase 1 studies and phase 2 enabling toxicity studies are expected to be completed in the third quarter of 2018.

The first molecule produced by Pharmaxis’ drug discovery platform was sold to Boehringer Ingelheim in 2015 and is currently in phase 2 trials for NASH and Diabetic Retinopathy. The company has two more programmes that are rapidly moving towards the clinic.

Joe Anderson, Chief Executive Officer of Arix Bioscience, commented: “We are very pleased to have led Pharmaxis’ successful financing as it continues to build its position as a world leader in mechanism-based inhibitors of amine oxidases for patients suffering from fibrotic and inflammatory diseases. This is the first investment in a public company that Arix has led and reflects our flexibility and commitment to providing capital to innovative companies with strong leadership teams. We see a number of opportunities to help build high value companies through our VIPE strategy.

“In addition, it is our first investment in a company based in Australia, demonstrating our growing global reach, where we see a rich landscape of world-class science and high quality companies. We look forward to supporting Pharmaxis’ ambitious and internationally-experienced management team in developing these potentially first-in-class treatments for patients while we continue to build value for our shareholders.”

Gary Phillips, Chief Executive Officer of Pharmaxis, commented: “We are delighted with the strong support for the capital raising from Arix and our existing shareholders, as we head into partnering negotiations for our LOXL2 inhibitor program. This will put Pharmaxis in a strong position to negotiate the best partnering outcome and continue investing in its preclinical pipeline. Pharmaxis will also be strengthened by Arix’s extensive global networks and deep industry knowledge, which will help accelerate the company’s next phase of growth and development.”



For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry,
Head of Investor Relations
+44 (0)20 7290 1072

Optimum Strategic Communications
Mary Clark, Supriya Mathur, Hollie Vile
+44 203 714 1787

Burns McClellan (US Media & IR Enquiries)
Lisa Burns, Bill Slattery Jr., Nancie Steinberg
+1 212-213-0006

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit

About Pharmaxis

Pharmaxis (ACN 082 811 630) is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis is marketed in Europe, Russia and Australia. Its product Aridol® for the assessment of asthma is sold in Europe, Australia and Asia. The company’s development pipeline is centred on its expertise in amine oxidase chemistry and includes a series of Lysyl Oxidase Inhibitors under clinical development targeting fibrotic diseases of the heart, kidney, liver and lung. In May 2015, Boehringer Ingelheim acquired the Pharmaxis investigational drug PXS- 4728A, a potent inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), to develop it for the treatment of the liver-related condition Non-alcoholic Steatohepatitis (NASH) and other inflammatory diseases. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company’s head office, manufacturing and research facilities are located in Sydney, Australia.

For more information about Pharmaxis, please see


Record changed: 2018-10-06


Picture [iito] Made Without Love 650x80px

More documents for Arix Bioscience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top